Timing of Death from Tumor Recurrence after Curative Gastrectomy for Gastric Cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 2, 2004, Pages 205-209

  Sakar, Burak ^a   Karagol, Hakan ^a   Gumus, Mahmut ^a   Basaran, Mert ^a   Kaytan, Esra ^b   Argon, Andac ^a   Ustuner, Zeki ^a   Bavbek, Sevil E ^a   Bugra, Dursun ^c   Aykan, Faruk N ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Gastric cancer; Lymph node status; Tumor recurrence

Indexed keywords

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GASTRECTOMY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; POSTOPERATIVE CARE; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURGICAL TECHNIQUE; SURVIVAL RATE; TIME OF DEATH; TUMOR LOCALIZATION; TUMOR RECURRENCE;

ADENOCARCINOMA; FEMALE; GASTRECTOMY; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 11144356323     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000092703.12189.a2     Document Type: Article

References (25)

1. Whelan SL, Parkin DM, Masuyer E, eds. Trends in Cancer Incidence and Mortality. Lyon, France: IARC Scientific Publications, 1993. (IARC scientific publication no. 102.)
2. Icli F, Celik I, Aykan F, et al. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group. Cancer. 1998;83:2475-2480.
3. Alexander H, Kelsen D, Tepper J. Cancer of the stomach. In: De Vita V, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia: JB Lippincott; 1993:818-848.
4. American Joint Committee on Cancer. Manual for Staging of Cancer. 4th ed. Philadelphia: JB Lippincott; 1993.
5. Shiarishi N, Inomata M, Osawa N, et al. Early and late recurrence after gastrectomy for gastric carcinoma. Cancer. 2000;89:255-261.
6. Adachi Y, Oshiro T, Mori M, et al. Prediction of early and late recurrence after curative resection for gastric carcinoma. Cancer. 1996;77:2445-2448.
7. Maehara Y, Kakeji Y, Oda S, et al. Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer. Br J Cancer. 2000;83:986-991.
8. Siewert JR, Bottcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449-461.
9. Douglass HO Jr, Nava HR. Gastric adenocarcinoma management of the primary disease. Semin Oncol. 1985;12:32-45.
10. Gouzi JL, Huguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum: a French prospective controlled study. Ann Surg. 1989;209:162-166.
11. Sugimachi K, Kodama Y, Kumashiro R, et al. Critical evaluation of prophylactic splenectomy in total gastrectomy for the stomach cancer. Gann. 1980;71:704-709.
12. Suehiro S, Nagasue N, Ogawa Y, et al. The negative effect of splenectomy on the prognosis of gastric cancer. Am J Surg. 1984;148:645-648.
13. Green D, Ponce de Leon S, Leon-Rodriguez E, et al. Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival. Am J Clin Oncol. 2002;25:84-89.
14. Johnson H Jr, Belluco C, Masood S, et al. The value of flow cytometric analysis in patients with gastric cancer. Arch Surg. 1993;128:314-317.
15. Nanus DM, Kelsen DP, Niedzwiecki D, et al. Flow cytometry as a predictive indicator in patients with operable gastric cancer. J Clin Oncol. 1989;7:1105-1112.
16. Wanebo H, Kennedy B, Chmiel J, et al. Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg. 1993;218:583-592.
17. Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c-erbB-2 protein in gastric cancer: its correlation with long-term survival of patients. Cancer. 1993;72:3179-3184.
18. Mizutani T, Onda M, Tokunaga A, et al. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer. 1993;72:2083-2088.
19. Joypaul BU, Hopwood D, Newman EL, et al. The prognostic significance of the accumulation of p53 tumor-suppressor gene protein in gastric adenocarcinoma. Br J Cancer. 1994;69:943-946.
20. Kakeji Y, Korenaga D, Tsujitani S, et al. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer. 1993;67:589-593.
21. 3 total gastrectomy for antral cancer. Ann Surg. 1994;200:176-182.
22. 2 gastrectomy for gastric carcinoma. Br J Surg. 1988;75:110-112.
23. Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in Western patients with gastric cancer based on a new concept: a prospective long term follow-up study. Surgery. 1998;123:573-578.
24. Otsuji E, Yamaguchi T, Sawai K, et al. Recent advances in surgical treatment have improved the survival of patients with gastric carcinoma. Cancer. 1998;82:1233-1237.
25. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.